BeiGene, Ltd. Files 8-K Report
Ticker: BEIGF · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: BGNE
TL;DR
BeiGene filed an 8-K. Check for updates on financials and operations.
AI Summary
On March 8, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing provides an update on BeiGene's corporate and financial activities, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without immediate disclosure of significant negative events.
Key Players & Entities
- BeiGene, Ltd. (company) — Registrant
- Mourant Governance Services (Cayman) Limited (company) — Agent for service of process
FAQ
What is the primary purpose of this 8-K filing for BeiGene, Ltd.?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations.
When was this 8-K report filed?
The report was filed on March 8, 2024.
What is BeiGene, Ltd.'s principal executive office address?
The principal executive offices are located at c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands.
What is BeiGene, Ltd.'s IRS Employer Identification Number?
BeiGene, Ltd.'s IRS Employer Identification Number is 98-1209416.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 680 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-03-08 06:01:45
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
Filing Documents
- bgne-20240308.htm (8-K) — 35KB
- 0001651308-24-000021.txt ( ) — 158KB
- bgne-20240308.xsd (EX-101.SCH) — 2KB
- bgne-20240308_lab.xml (EX-101.LAB) — 22KB
- bgne-20240308_pre.xml (EX-101.PRE) — 13KB
- bgne-20240308_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On March 8, 2024, BeiGene, Ltd. ("BeiGene") filed patent infringement suits under the Hatch-Waxman Act against Sandoz Inc. ("Sandoz") and separately against MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. (collectively "MSN") in the United States District Court for the District of New Jersey. The patent infringement suits are in response to Sandoz's and MSN's notices to BeiGene concerning the filings of Abbreviated New Drug Applications ("ANDAs") with the U.S. Food and Drug Administration ("FDA"), seeking FDA approval to market a generic version of BRUKINSA (zanubrutinib) along with "Paragraph IV certifications" challenging certain BRUKINSA Orange Book patents for invalidity, unenforceability and/or non-infringement. According to the notices, neither Sandoz nor MSN have challenged BRUKINSA's composition of matter patent, which remains intact and protects BRUKINSA from generic competition until its expiration in 2034. BeiGene's complaints allege that by filing the ANDAs, each of Sandoz and MSN has infringed BRUKISNA's Orange Book patents included in their respective Paragraph IV certifications, and seek a permanent injunction to prevent Sandoz and MSN from commercializing a generic version of BRUKINSA until the expiration of the asserted patents. ANDA litigation is common in the U.S. pharmaceutical industry. We may receive additional notices from other generic drug companies and may file additional ANDA lawsuits in the future.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: March 8, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel